Search Result

Results for "

TCFS

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Akt (1) Antibiotic (4) Apoptosis (4) Autophagy (1) Bacterial (4) Biochemical Assay Reagents (1) Casein Kinase (1) FAAH (1) Fungal (2) Isotope-Labeled Compounds (1) p38 MAPK (1) Small Interfering RNA (siRNA) (12) Wnt (12) β-catenin (19)
By Research Areas:	Cancer (27) Cardiovascular Disease (2) Infection (4) Inflammation/Immunology (3) Metabolic Disease (2)
Oligonucleotides:	Pre-designed siRNA Sets (12) siRNAs (12)

Inhibitors & Agonists

Biochemical Assay Reagents

Peptides

Isotope-Labeled Compounds

Oligonucleotides

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-19987

BML-284 25+ Cited Publications	Wnt	Cancer
BML-284 is a potent and cell-permeable Wnt signaling activator. BML-284 induces TCF-dependent transcriptional activity with an EC₅₀ of 700 nM .

HY-100760

Toxoflavin 5 Publications Verification Xanthothricin; Toxoflavine; PKF-118-310	β-catenin Bacterial Antibiotic	Infection Cancer
Toxoflavin (Xanthothricin) is an antagonist of *transcription factor 4 (TCF4)/β-catenin complex, also acts as an inhibitor of KDM4A*, with antitumor activity . Antibiotic properties.

HY-W143136

6-(N-Trifluoroacetyl)caproic acid NHS TCFS	Biochemical Assay Reagents	Others
6-(N-Trifluoroacetyl)caproic acid NHS (TCFS) is a biochemical reagent.

HY-164467

CCT070535	Wnt	Cancer
CCT070535 blocks *TCF*-dependent transcription at the TCF level, with GI₅₀ values of 17.6 μM, 11.1 μM, 11.8 μM and 13.4 μM in HT29 (APC mutant), HCT116 (oncogenic β-catenin), SW480 (APC mutant) and SNU475 (Axin mutant) cells, respectively .

HY-19987A

BML-284 hydrochloride	Wnt	Cancer
BML-284 hydrochloride is a potent and cell-permeable Wnt signaling activator. BML-284 induces TCF-dependent transcriptional activity with an EC₅₀ of 700 nM .

HY-124826

BC21 NSC 109268	β-catenin	Cancer
BC21 (NSC 109268) is a *β-catenin/Tcf4* inhibitor with an IC₅₀ of 5 μM. BC21 effectively inhibits the binding of β-catenin to Tcf4-derived peptides and suppresses β-catenin/Tcf4-driven reporter gene activity. BC21 can be utilized in cancer research .

HY-RS14299

TCF12 Human Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
TCF12 Human Pre-designed siRNA Set A contains three designed siRNAs for TCF12 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

TCF12 Human Pre-designed siRNA Set A TCF12 Human Pre-designed siRNA Set A

HY-RS14300

TCF15 Human Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
TCF15 Human Pre-designed siRNA Set A contains three designed siRNAs for TCF15 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

TCF15 Human Pre-designed siRNA Set A TCF15 Human Pre-designed siRNA Set A

HY-RS14301

TCF19 Human Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
TCF19 Human Pre-designed siRNA Set A contains three designed siRNAs for TCF19 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

TCF19 Human Pre-designed siRNA Set A TCF19 Human Pre-designed siRNA Set A

HY-RS14302

TCF20 Human Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
TCF20 Human Pre-designed siRNA Set A contains three designed siRNAs for TCF20 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

TCF20 Human Pre-designed siRNA Set A TCF20 Human Pre-designed siRNA Set A

HY-RS14303

TCF21 Human Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
TCF21 Human Pre-designed siRNA Set A contains three designed siRNAs for TCF21 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

TCF21 Human Pre-designed siRNA Set A TCF21 Human Pre-designed siRNA Set A

HY-RS14304

TCF23 Human Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
TCF23 Human Pre-designed siRNA Set A contains three designed siRNAs for TCF23 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

TCF23 Human Pre-designed siRNA Set A TCF23 Human Pre-designed siRNA Set A

HY-RS14305

TCF25 Human Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
TCF25 Human Pre-designed siRNA Set A contains three designed siRNAs for TCF25 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

TCF25 Human Pre-designed siRNA Set A TCF25 Human Pre-designed siRNA Set A

HY-RS14306

TCF3 Human Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
TCF3 Human Pre-designed siRNA Set A contains three designed siRNAs for TCF3 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

TCF3 Human Pre-designed siRNA Set A TCF3 Human Pre-designed siRNA Set A

HY-RS14307

TCF4 Human Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
TCF4 Human Pre-designed siRNA Set A contains three designed siRNAs for TCF4 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

TCF4 Human Pre-designed siRNA Set A TCF4 Human Pre-designed siRNA Set A

HY-RS14308

TCF7 Human Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
TCF7 Human Pre-designed siRNA Set A contains three designed siRNAs for TCF7 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

TCF7 Human Pre-designed siRNA Set A TCF7 Human Pre-designed siRNA Set A

HY-RS14309

TCF7L1 Human Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
TCF7L1 Human Pre-designed siRNA Set A contains three designed siRNAs for TCF7L1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

TCF7L1 Human Pre-designed siRNA Set A TCF7L1 Human Pre-designed siRNA Set A

HY-RS14310

TCF7L2 Human Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
TCF7L2 Human Pre-designed siRNA Set A contains three designed siRNAs for TCF7L2 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

TCF7L2 Human Pre-designed siRNA Set A TCF7L2 Human Pre-designed siRNA Set A

HY-108441

CCT031374 hydrobromide	β-catenin	Cancer
CCT 031374 hydrobromid is a potent inhibitor of β-catenin/transcription factor (TCF) complex signaling. CCT031374 inhibits TCF-dependent transcription of genes of Wnt signaling pathway. CCT 031374 has antitumor activity .

HY-100760S

Toxoflavin-13C4	Isotope-Labeled Compounds β-catenin Bacterial Antibiotic	Infection Cancer
Toxoflavin- ¹³C₄ is the ¹³C-labeled Toxoflavin. Toxoflavin (Xanthothricin) is an antagonist of transcription factor 4 (TCF4)/β-catenin complex, also acts as an inhibitor of KDM4A, with antitumor activity[1][2]. Antibiotic properties.

HY-149858

β-catenin-IN-7	Wnt	Cancer
β-catenin-IN-7 (Compound 9) is a β-catenin inhibitor. β-catenin-IN-7 inhibits the interaction between β-catenin and Tcf-4, and inhibits Wnt-dependent target gene expression. β-catenin-IN-7 has anti-cancer activity .

HY-162838

TCF199	Others	Others
TCF199 is an allosteric stabilizer that stabilizes the 14-3-3/TAZ peptide interaction, binding to the 14-3-3ζ/E R α peptide and 14-3-3ζ/Chibby peptide. TCF199 has a Kd value of 122 μM for its interaction with 14-3-3/TAZ .

HY-101486

LF3 5+ Cited Publications	β-catenin	Cancer
LF3 is an antagonist of the *β-Catenin/TCF4* interaction with antitumor activity; has an IC₅₀ of 1.65 μM.

HY-157126

Pterostilbene-isothiocyanate PTER-ITC	β-catenin	Cancer
Pterostilbene-isothiocyanate (PTER-ITC) exhibits potent anticancereffects in vitro. Pterostilbene-isothiocyanate against human osteosarcoma cells by abrogating the β-catenin/TCF-4 interaction .

HY-11035

WAY-262611 5+ Cited Publications	β-catenin	Cancer
WAY-262611 is a wingless β-Catenin agonist that increases bone formation rate with an EC₅₀ of 0.63 μM in TCF-Luciferase assay. WAY-262611 is also a Dkk1 inhibitor.

HY-109049

Adavivint 5+ Cited Publications SM04690; Lorecivivint	Wnt	Inflammation/Immunology Cancer
Adavivint (SM04690; Lorecivivint) is a potent and selective inhibitor of canonical Wnt signaling, with an EC₅₀ of 19.5 nM via a high-throughput TCF/LEF-reporter assay in SW480 colon cancer cells .

HY-103462

TC-F2	FAAH	Cardiovascular Disease Metabolic Disease Inflammation/Immunology Cancer
TC-F2 is a reversible non-covalent binding inhibitor of fatty acid amide hydrolase (FAAH) with an IC₅₀ of 28 nM. FAAH is involved in many human diseases, particularly cancer, pain and inflammation as well as neurological, metabolic and cardiovascular disorders .

HY-B1360

Chlorquinaldol 5 Publications Verification Chloquinan	Antibiotic Bacterial Fungal β-catenin Apoptosis	Infection Cancer
Chlorquinaldol (Chloquinan) is an antibacterial agent with the potential use in topical skin conditions and vaginal infections. Chlorquinaldol is a *β-catenin/TCF4* inhibitor, showing anti-proliferation, anti-migration, and apoptosis-inducing activity in cancer cells .

HY-119751

Hematein 1 Publications Verification	Casein Kinase Akt Wnt Apoptosis	Cancer
Hematein is a oxidation product of hematoxylin acted as a dye . Hematein is an allosteric casein kinase II inhibitor with an IC₅₀ of 0.74 μM. Hematein inhibits Akt/PKB Ser129 phosphorylation, the *Wnt/TCF* pathway and increases apoptosis in lung cancer cells .

HY-18959

CWP232228 5 Publications Verification	β-catenin Wnt	Cancer
CWP232228, a highly potent selective Wnt/β-catenin signaling inhibitor, antagonizes binding of β-catenin to T-cell factor (TCF) in the nucleus. CWP232228 suppresses tumor formation and metastasis without toxicity through the inhibition of the growth of breast and liver cancer stem cells (CSCs) .

HY-P10392AF

fStAx-35R TFA	β-catenin	Cancer
fStAx-35R TFA is the hydrocarbon-stapled peptide. fStAx-35R TFA inhibits Wnt/β-catenin signaling pathway by disrupting the β-catenin-TCF interaction. fStAx-35R TFA can be used in cancer research .

HY-122649

UU-T01	β-catenin	Cancer
UU-T01 is a selective inhibitor for β-Catenin/T-cell factor 4 protein-protein interaction (β-catenin/Tcf PPI) with an K_i value of 3.14 µM. UU-T01 is directly combined with β-catenin, and the K_D value is 0.531 µM .

HY-B1360R

Chlorquinaldol (Standard)	Antibiotic Bacterial Fungal β-catenin Apoptosis	Infection Cancer
Chlorquinaldol (Standard) is the analytical standard of Chlorquinaldol. This product is intended for research and analytical applications. Chlorquinaldol (Chloquinan) is an antibacterial agent with the potential use in topical skin conditions and vaginal infections. Chlorquinaldol is a *β-catenin/TCF4* inhibitor, showing anti-proliferation, anti-migration, and apoptosis-inducing activity in cancer cells .

HY-117233

UU-T02 1 Publications Verification	β-catenin Wnt	Metabolic Disease Cancer
UU-T02 is a novel potent, selective small-molecule inhibitor of β-Catenin/T-cell factor protein-protein interaction *(β-catenin/Tcf* PPI) with a K_i of 1.36 μM . UU-T02 inhibits canonical Wnt** signaling and the growth of colorectal cancer cells .

HY-P10392

aStAx-35R	β-catenin Wnt	Cancer
aStAx-35R, a stapled peptide, antagonizes nuclear form of β-catenin and inhibits Wnt signaling. aStAx-35R inhibits competitively the binding of β-catenin to TCF4. aStAx-35R selectively induces growth inhibition of Wnt-dependent cancer cells .

HY-119966

CCT036477	Wnt β-catenin	Cancer
CCT036477 is a Wnt/β-catenin pathway inhibitor. CCT036477 blocks transcription at β-catenin without altering its levels. CCT036477 inhibits proliferation of various cancer cells, development of embryos, and expression of Wnt target genes (PPARδ, Cyclin D1, TCF4, and ID2) .

HY-14428

ICG-001 Maximum Cited Publications 47 Publications Verification	β-catenin Apoptosis	Cancer
ICG-001 is an inhibitor of *β-catenin/TCF* mediated transcription. ICG-001 works by specifically binding to cyclic AMP response element-binding protein with an IC₅₀ of 3 μM. ICG-001 selectively blocks the β-catenin/CBP interaction without interfering with the β-catenin/p300 interaction.

HY-115543

β-catenin-IN-37	β-catenin	Cancer
β-catenin-IN-37 is a selective β-Catenin/T-cell factor protein-protein interaction (β-catenin/Tcf PPI) inhibitor. β-catenin-IN-37 inhibits canonical Wnt signaling and the growth of colorectal cancer cells SW480 and HCT116 with the IC₅₀ values of 20 μM and 31 μM, respectively .

HY-P10392B

aStAx-35R TFA	β-catenin Wnt	Cancer
aStAx-35R TFA, a stapled peptide, antagonizes nuclear form of β-catenin and inhibits Wnt signaling. aStAx-35R TFA inhibits competitively the binding of β-catenin to TCF4. aStAx-35R TFA selectively induces growth inhibition of Wnt-dependent cancer cells .

HY-117163

FzM1.8	Wnt β-catenin	Cancer
FzM1.8 derives from FzM1, is an allosteric agonist of FZD4 with pEC₅₀ of 6.4. FzM1.8 binds to FZD4 and activates the WNT/β-catenin pathway, by promoting TCF/LEF transcriptional activity in the absence of any WNT ligand. FzM1.8 binding stabilizes FZD4 with an increased affinity for heterotrimeric G protein and stimulates the release of the Gβγ subunit that in turn activates PI3K .

HY-100115

TA-02 2 Publications Verification	p38 MAPK Autophagy	Cardiovascular Disease Inflammation/Immunology Cancer
TA-02, an analog of SB 203580 (HY-10256), is a p38 MAPK inhibitor with an IC₅₀ of 20 nM. TA-02 especially inhibits TGFBR-2. TA-02 exhibits similar cardiogenic properties as SB 203580 and SB 202190 (HY-10295) .

6-(N-Trifluoroacetyl)caproic acid NHS TCFS	Biochemical Assay Reagents
6-(N-Trifluoroacetyl)caproic acid NHS (TCFS) is a biochemical reagent.

Cat. No.	Product Name	Target	Research Area

HY-P10392AF

fStAx-35R TFA	β-catenin	Cancer
fStAx-35R TFA is the hydrocarbon-stapled peptide. fStAx-35R TFA inhibits Wnt/β-catenin signaling pathway by disrupting the β-catenin-TCF interaction. fStAx-35R TFA can be used in cancer research .

HY-P10392B

aStAx-35R TFA	β-catenin Wnt	Cancer
aStAx-35R TFA, a stapled peptide, antagonizes nuclear form of β-catenin and inhibits Wnt signaling. aStAx-35R TFA inhibits competitively the binding of β-catenin to TCF4. aStAx-35R TFA selectively induces growth inhibition of Wnt-dependent cancer cells .

HY-P10392

aStAx-35R	β-catenin Wnt	Cancer
aStAx-35R, a stapled peptide, antagonizes nuclear form of β-catenin and inhibits Wnt signaling. aStAx-35R inhibits competitively the binding of β-catenin to TCF4. aStAx-35R selectively induces growth inhibition of Wnt-dependent cancer cells .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: